Prostate cancer is one of the most common cancers in men, and risk increases with age. Management depends on the stage of disease and other co-morbidities. Hormone-based therapy is an integral part of management for patients with advanced disease. Abiraterone 500 mg is one of these therapies.
Its existing application in prostate carcinoma has further escalated demand among medicine dealers for oncology-specific medications. For a company looking to expand into the oncology division, an Abiraterone 500 mg Franchise can offer a dedicated product set to complement the MITS Oncology selections.
What Is Abiraterone 500mg?
Abiraterone acetate is an oral medication used with other medications for the treatment of castration-resistant and metastatic prostate cancer. It is part of the class of medications known as androgen biosynthesis inhibitors.
Abiraterone is an anti-androgen and works by inhibiting an enzyme called CYP17, which is involved in the production of androgens (and has further downstream effects of reducing the production of adrenal hormones). Androgens are the hormones that stimulate the growth of prostate cancers that are hormone-dependent.
This 500 mg strength is supplied as an oral tablet. The dose, duration, and co-administration of other medicines are determined by diagnosis and regulatory authorities and must only be administered under physician supervision.
How Does Abiraterone 500mg Work?
Prostate cancer cells can also use androgens to grow, and normal androgen deprivation therapy reduces the amount of androgen production by the testes, yet small quantities can be produced by other means such as preadrenal.
Abiraterone is effective in this, as it has an action to inhibit CYP17, which is a cytochrome P450 enzyme involved in the production of androgens in the Leydig cells of the testes, the adrenal glands, and tumor tissue in the prostate. Abiraterone reduces androgen production from several sources in the body, which is why it has an established role in selected prostate cancer treatment settings.
Commonly used with androgen deprivation therapy and a corticosteroid, given following the licensed indication and treatment protocol.
Benefits of Abiraterone 500mg in Prostate Cancer Treatment
Helps Reduce Androgen Production
The primary therapeutic role of abiraterone is its suppression of androgen production. Since certain prostate cancer cells are dependent on circulating androgens for growth, their suppression can improve disease control.
Supports Treatment of Advanced Prostate Cancer
Abiraterone is used in some specific advanced prostate cancer situations, including some patients with metastatic disease. Clinical studies have established its role in specific prostate cancer treatment settings and combinations.
Convenient Oral Form
Abiraterone is provided as an oral tablet and so can easily be incorporated into a patient’s treatment plan without the need for the drug’s administration via infusion. The oral treatment in oncology is still yet to call for regular follow-up and medical monitoring.
Established Oncology Medicine
Abiraterone is already established in the treatment of prostate cancer. From a small number of therapeutic indications, a product with accepted therapeutic use can be an important inclusion into a specialist onco-pharmaceuticals product range.
Why Does Abiraterone 500mg Matter for Your Franchise?
For a distributor, introducing a known oncology formulation to build a dedicated range for healthcare markets. Distributors seeking to build a portfolio with a main focus on cancer medicines may wish to stock what comes next: market-appropriate products for the treatment of prostate cancer.
An Abiraterone 500 mg PCD Franchise offers business associates the opportunity to market a specialized oncology product in a designated territory. However, the profitability of a franchise is influenced by a host of other factors like quality of product, steady supply, good pricing presentation, regulatory issues, and company focus.
For a distributor, introducing a known oncology formulation can help build a dedicated range for healthcare markets.
Why Choose MITS Oncology?
MITS Oncology is involved in pharmaceutical products of high quality for tailored specialized healthcare segments and also offers opportunities for the business partners who are willing to target the oncology market.
When choosing a pharmaceutical franchise partner, distributors will examine the company for dependable product supply, quality production, clear packaging, clear terms of business, and prompt, responsive support. All of these factors will ease the partner’s development of a territory.
MITS Oncology offers an opportunity for pharma distributors to develop a focused oncology portfolio of some of the more commonly used drugs that would cater to various therapeutic needs. An Abiraterone 500 mg franchise can be viewed as a viable proposition for such businesses.
Conclusion
Abiraterone 500 mg is a well-established oncology medicine used in particular circumstances for the treatment of advanced prostate cancer. It can be used to give control of hormone-dependent prostate cancer in appropriate treatment protocols by its action on cytochrome p450 (17) by reducing androgen production.
For pharmaceutical distributors, the therapeutic nature of these indications makes Abiraterone 500mg Franchise and Abiraterone 500mg PCD Franchise opportunities relevant to an oncology-based portfolio. MITS Oncology will offer partners an opportunity to tap into the specialized field of oncology by offering a quality-assured range of products, backed up with a strong supply chain, regulations, and business support.
FAQs
1. What is Abiraterone 500mg used for?
Abiraterone 500mg is used with other treatments for certain advanced forms of prostate cancer under the supervision of a healthcare professional.
2. How does Abiraterone 500mg work?
It blocks the CYP17 enzyme involved in androgen production, thereby reducing androgen levels that can support prostate cancer growth.
3. What is an Abiraterone 500mg Franchise?
It is a pharmaceutical business opportunity through which a partner markets and distributes an Abiraterone 500mg product within an agreed territory.
4. Why is Abiraterone relevant to an oncology franchise?
Abiraterone has an established role in selected prostate cancer treatment settings, making it a relevant formulation for an oncology-focused product portfolio.
5. Is Abiraterone 500mg a prescription medicine?
Yes. Abiraterone is a prescription oncology medicine and should be used according to the advice of a qualified healthcare professional.
6. Why consider MITS Oncology for an Abiraterone 500mg PCD Franchise?
MITS Oncology offers pharmaceutical business opportunities for partners interested in specialised oncology products, with emphasis on product availability, quality, and franchise support.